Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


Sage Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

May 3, 2018
Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness

May 3, 2018
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 24, 2018
Sage Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 3, 2018

Read More News

Associated Team Members

Kevin Starr
Partner